The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Open accessAbstract
Background —Elevated plasma concentrations of C-reactive protein (CRP) are associated with increased cardiovascular risk. We evaluated whether long-term therapy with pravastatin, an agent that reduces cardiovascular risk, might alter levels of this inflammatory parameter. Methods and Results —CRP levels were measured at baseline and at 5 years in 472 randomly selected participants in the Cholesterol and Recurrent Events (CARE) trial who remained free of recurrent coronary events during follow-up. Overall, CRP levels at baseline and at 5 years were highly correlated ( r =0.60, P <0.001). However, among those allocated to placebo, median CRP levels and the mean change in CRP tended to increase over time (median change, +4.2%; P =0.2 and mean change, +0.07 mg/dL; P =0.04). By contrast, median CRP levels and the mean change in CRP decreased over time among those allocated to pravastatin (median change, −17.4%; P =0.004 and mean change, −0.07 mg/dL; P =0.002). Thus, statistically significant differences were observed at 5 years between the pravastatin and placebo groups in terms of median CRP levels (difference, −21.6%; P =0.007), mean CRP levels (difference, −37.8%; P =0.002), and absolute mean change in CRP (difference, −0.137 mg/dL; P =0.003). These effects persisted in analyses stratified by age, body mass index, smoking status, blood pressure, and baseline lipid levels. Attempts to relate the magnitude of change in CRP to the magnitude of change in lipids in both the pravastatin and placebo groups did not reveal any obvious relationships. Conclusions —Among survivors of myocardial infarction on standard therapy plus placebo, CRP levels tended to increase over 5 years of follow-up. In contrast, randomization to pravastatin resulted in significant reductions in this inflammatory marker that were not related to the magnitude of lipid alterations observed. Thus, these data further support the potential for nonlipid effects of this agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citationInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,357
Tuomilehto, J., Vidgren, G., Toivanen, L., Tuomilehto-Wolf, E., Kohtamaki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M., & Koskela, P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,692
Ridker, P. M., Buring, J. E., Shih, J., Matias, M., & Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.98.8.731 · Cited by 1,642
Self-citationProduction of C-reactive protein and risk of coronary events in stable and unstable angina
Haverkate, E., Thompson, S. G., Pyke, S. D., Gallimore, J. R., & Group, M. B. P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07591-5 · Cited by 1,500
Cited by
Items 101–146 of 146
Anti-inflammatory therapeutics for the treatment of atherosclerosis
Charo, I. F., & Taub, R. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3444 · Cited by 306
Liao, J. K. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.009 · Cited by 304
C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study
Wilson, P. W. F., Pencina, M., Jacques, P., Selhub, J., D'Agostino, R., & O'Donnell, C. J. (2008) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.831198 · Cited by 299
Ridker, P. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.028 · Cited by 290
Self-citationCOVID-19 and comorbidities: a systematic review and meta-analysis
Gold, M. S., Sehayek, D., Gabrielli, S., Zhang, X., McCusker, C., & Ben-Shoshan, M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1786964 · Cited by 289
C-Reactive Protein and Glycemic Control in Adults With Diabetes
King, D. E., Mainous, A. G., Buchanan, T. A., & Pearson, W. S. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1535 · Cited by 280
Inflammatory pathways in atherosclerosis and acute coronary syndromes
Plutzky, J. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01924-5 · Cited by 279
Diabetes-Induced Oxidative Stress and Low-Grade Inflammation in Porcine Coronary Arteries
Zhang, L., Zalewski, A., Liu, Y., Mazurek, T., Cowan, S., Martin, J. L., Hofmann, S. M., Vlassara, H., & Shi, Y. (2003) · Circulation · doi:10.1161/01.cir.0000080378.96063.23 · Cited by 279
C‐Reactive Protein (CRP)‐Lowering Agents
Prasad, K. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00033.x · Cited by 272
RIDKER, P. M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03404.x · Cited by 270
Self-citationAlbert, M. A., Glynn, R. J., & Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000080289.72166.cf · Cited by 269
Self-citationBeyond lipid lowering: the role of statins in vascular protection
Liao, J. K. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00195-x · Cited by 266
Independent Association Between Plasma Leptin and C-Reactive Protein in Healthy Humans
Shamsuzzaman, A. S. M., Winnicki, M., Wolk, R., Svatikova, A., Phillips, B. G., Davison, D. E., Berger, P. B., & Somers, V. K. (2004) · Circulation · doi:10.1161/01.cir.0000127960.28627.75 · Cited by 261
Sesmilo, G., Biller, B. M. K., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., & Klibanski, A. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-2-200007180-00010 · Cited by 257
Self-citationAnticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker, P. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313129 · Cited by 260
Self-citationRidker, P. M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00774-4 · Cited by 260
Self-citationLipoprotein-Associated Phospholipase A
Krumholz, H. (2001) · Journal watch · doi:10.1056/jc200101050000008 · Cited by 254
The lipid and non-lipid effects of statins
Wierzbicki, A. S., Poston, R., & Ferro, A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00055-x · Cited by 253
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Ridker, P. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.119214 · Cited by 206
Self-citationWassmann, S., Faul, A., Hennen, B., Scheller, B., Böhm, M., & Nickenig, G. (2003) · Circulation Research · doi:10.1161/01.res.0000099503.13312.7b · Cited by 177
Khush, K. K., Waters, D. D., Bittner, V., Deedwania, P. C., Kastelein, J. J. P., Lewis, S. J., & Wenger, N. K. (2007) · Circulation · doi:10.1161/circulationaha.106.625574 · Cited by 172
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Clinical implications for statin pleiotropy
Liao, J. K. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000191913.16321.60 · Cited by 139
Kandelouei, T., Abbasifard, M., Imani, D., Aslani, S., Razi, B., Fasihi, M., Shafiekhani, S., Mohammadi, K., Jamialahmadi, T., Reiner, Ž., et al. (2022) · Mediators of Inflammation · doi:10.1155/2022/8732360 · Cited by 136
Growth Hormone and Cardiovascular Risk Factors
Gola, M., Bonadonna, S., Doga, M., & Giustina, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0545 · Cited by 135
Kang, S., Wu, Y., & Li, X. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.08.005 · Cited by 126
Wang, T.-D., Chen, W.-J., Lin, J.-W., Cheng, C.-C., Chen, M.-F., & Lee, Y.-T. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00296-x · Cited by 125
Kuo, H.-K., Bean, J. F., Yen, C.-J., & Leveille, S. G. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.4.380 · Cited by 115
Sahebkar, A., Di Giosia, P., Stamerra, C. A., Grassi, D., Pedone, C., Ferretti, G., Bacchetti, T., Ferri, C., & Giorgini, P. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12905 · Cited by 116
Cholesterol-independent Effects of Statins and New Therapeutic Targets: Ischemic Stroke and Dementia
Miida, T., Hirayama, S., & Nakamura, Y. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.253 · Cited by 97
Inflammatory cardiovascular risk markers in women with hypopituitarism
Sesmilo, G., Miller, K. K., Hayden, D., & Klibanski, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8087 · Cited by 97
Boos, C. J., & Lip, G. Y. H. (2005) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001858 · Cited by 84
LaCroix, A. Z., Gray, S. L., Aragaki, A., Cochrane, B. B., Newman, A. B., Kooperberg, C. L., Black, H., Curb, J. D., Greenland, P., & Woods, N. F. (2008) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/63.4.369 · Cited by 84
Gao, F., Linhartova, L., Johnston, A. M., & Thickett, D. R. (2008) · British Journal of Anaesthesia · doi:10.1093/bja/aem406 · Cited by 83
Obisesan, T. O., Leeuwenburgh, C., Phillips, T., Ferrell, R. E., Phares, D. A., Prior, S. J., & Hagberg, J. M. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000140060.13203.22 · Cited by 83
Effect of statins on the progression of bioprosthetic aortic valve degeneration
Antonini-Canterin, F., Zuppiroli, A., Popescu, B. A., Granata, G., Cervesato, E., Piazza, R., Pavan, D., & Nicolosi, G. L. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.08.066 · Cited by 81
Heilbronn, L. K., & Clifton, P. M. (2002) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(02)00187-0 · Cited by 80
Vincenzi, B., Stock, S., Borba, C. P. C., Cleary, S. M., Oppenheim, C. E., Petruzzi, L. J., Fan, X., Copeland, P. M., Freudenreich, O., Cather, C., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.08.021 · Cited by 67
Estimating cardiovascular disease risk and the metabolic syndrome: a Framingham view
Wilson, P. W. F. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.03.012 · Cited by 65
The effect of n-3 fatty acids on C-reactive protein levels in patients with chronic renal failure
Madsen, T., Schmidt, E. B., & Christensen, J. H. (2007) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2007.03.003 · Cited by 52
C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?
Blake, G. J., & Ridker, P. M. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00227.2003 · Cited by 47
Self-citationKnudsen, S. H., & Pedersen, B. K. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0642-1 · Cited by 41
Do Statins Have Antidepressant Effects?
Köhler-Forsberg, O., Gasse, C., Berk, M., & Østergaard, S. D. (2017) · CNS Drugs · doi:10.1007/s40263-017-0422-3 · Cited by 31
Zgibor, J. C., Kuo, S., Emerson, S., Gittinger, P., Solano, F. X., Tilves, D., Maloney, M., & Davidson, M. B. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.07.004 · Cited by 10
Treatment with w-3 fatty acids reduces serum C-reactive protein concentration
Muhammad, K., Morledge, T., Sachar, R., Zeldin, A., Wolski, K., & Bhatt, D. (2011) · Clinical Lipidology · doi:10.2217/clp.11.54 · Cited by 10
Metadata
- Authors
- Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F., & Braunwald, E.
- Venue
- Circulation
- Published
- 1999-07-20
- Volume
- 100
- Issue
- 3
- Pages
- 230-235
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2145053304
- Cited by
- 1,478
- References
- 25
- FWCI
- 114.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.